Form 4: Director Nicole Lambert Receives Arcus Biosciences Equity

Arcus Biosciences director Nicole Lambert was granted 5,700 restricted stock units and 16,900 stock options as part of annual compensation.

Summary

• Director Nicole Lambert acquired 5,700 restricted stock units (RSUs) on June 11, 2026.
• Director Nicole Lambert was granted 16,900 stock options with an exercise price of $23.30.
• The total beneficial ownership for the director increased to 43,000 shares of common stock following these transactions.
• Both the RSUs and stock options are scheduled to vest on the earlier of June 11, 2027, or the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Vesting schedule provides retention incentive for the director over the next year.

Negatives

• Issuance of equity results in minor dilution to existing shareholders.

Risks

• Potential for accelerated vesting in the event of a change in control, which may impact future acquisition negotiations.

Future Outlook

The equity grants are standard compensation packages for board members, indicating no specific change in company strategy or financial guidance.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure long-term alignment with shareholder value.

Comparison to Industry Standards

• The grant of RSUs and options is consistent with standard compensation practices for non-employee directors in mid-cap biotech firms.
• Vesting periods of one year are typical for annual director equity refreshers.

Corporate Governance

Stakeholder Impact

• Shareholders experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of equity on June 11, 2027, or the next annual meeting.

Key Dates

Keywords

Arcus Biosciences, RCUS, Form 4, Insider Trading, Equity Compensation, Director Compensation